Our group evaluated the utility of molecularly targeted PET for imaging CD38 on MM cells in preclinical mouse models using radiolabeled daratumumab, [89Zr]-DFO-daratumumab [7]. This evidence concerns the gene CD38 and Miyoshi myopathy.